Introduction
============

Pancreatic cancer is one of the most lethal solid organ malignancies, with a 5-year survival rate of 6%, and is characterized by diagnostic difficulty, distant metastasis and aggressive local invasion at an early stage [@B1]-[@B3]. Despite the use of advanced imaging methods and image-guided biopsy procedures in differentiating pancreatic cancer from benign pancreatic diseases, diagnostic limitations still exist[@B4], [@B5]. Furthermore, these procedures have drawbacks, as they are invasive and expensive and can only be performed in experienced centers. In the search for simple and inexpensive methods, a wide range of serum biomarkers including carbohydrate antigen 19-9 (CA19-9), CA125, CA50, CA724, CA242 and carcinoembryonic antigen (CEA) have been studied in connection with pancreatic cancer [@B6]-[@B8]. Among these, the most common and best-studied marker for pancreatic cancer is CA19-9, which is reported to have a sensitivity ranging between 68% and 92% [@B9], [@B10]. However, Lewis antigen-negative individuals, comprising approximately 5 to 10% of the population, exhibit little or no secretion of CA19-9, which has been the major shortfall for CA19-9 as a biomarker [@B11]. Furthermore, it may lack sufficient sensitivity and specificity for certain patients with specific metastases or jaundice [@B12]-[@B14].

As a high-molecular-weight mucin-like glycoprotein, CA125 has been reported to be a marker for epithelial cell ovarian cancer [@B15]. Moreover, it has been detected in colorectal adenocarcinoma, duodenal minor papilla adenocarcinoma and cholangiocarcinoma [@B16]-[@B18]. It has only recently been recognized that CA125 also has an important clinical value for the detection of pancreatic cancer [@B19]-[@B23]. In this regard, our previous studies demonstrated that CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer [@B24]. Furthermore, CA125 also correlates with the metastasis-associated burden, and a preoperative serum combination of CEA+/CA125+/CA19-9 \> 1000 U/mL could be a useful preoperative predictor for the presence of micrometastasis in pancreatic cancer patients [@B25], [@B26].

Therefore, the present meta-analysis was performed to investigate the diagnostic value of CA125 and a CA125-based tumor marker panel, which could provide more reliable evidence that may help clinicians diagnose and treat pancreatic cancer.

Materials and Methods
=====================

Search strategy
---------------

A comprehensive and systematic literature review was undertaken by searching EMBASE, MEDLINE and Web of Science from inception to October 2016 using the terms \'pancreatic cancer/neoplasm/tumor/adenocarcinoma\' and \'CA125/Cancer Antigen 125/CA-125\' in combination with keywords, namely, \'diagnosis\', \'serum\' and \'biomarker\'. Two reviewers (Meng QC and Shi S) independently screened the titles, abstracts and full texts of selected studies to assess eligibility. The following inclusion criteria had to be fulfilled: (a) clinical studies (cohort and case-control) of patients with pancreatic cancer; (b) studies focusing on the relationship between serum CA125, CA19-9 or CEA concentration and pancreatic cancer; (c) serum samples obtained from patients with pancreatic cancer before treatment; (d) data regarding diagnostic accuracy, such as sensitivity and specificity. The exclusion criteria were as follows: (a) published in a non-English language; (b) no full text available; (c) literature published as reviews, case reports, letters, editorials and expert opinions. Any discrepancies between the reviewers were resolved by discussion or consultation with a third reviewer (Liang C).

Quality assessment
------------------

Two reviewers (Meng QC and Shi S) independently systematically assessed the methodological quality of each study using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies. The checklist of the tool is as follows: (1) patient selection; (2) conduct of the index test; (3) reference standard; (4) flow and timing. The studies could be considered to be of high quality if they enrolled all consecutive, or a random sample of, eligible patients, an index test was always conducted and interpreted prior to the reference standard, and all participants underwent the same reference standard testing method [@B27]. The assessment results were presented as low, high or unclear risk of bias/concerns regarding applicability for each checklist topic.

Data extraction
---------------

The data were reviewed and extracted independently by two reviewers (QC Meng and Shi S), and disagreements between the reviewers were resolved by a third reviewer (Liang C), using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [@B28]. The following information from each article was extracted: name of first author; year of publication; country of study; number of samples; origin of samples; cut-off criteria; the number of true positive (TP), false positive (FP), true negative (TN), and false negative (FN) results; and use of a CA125-based diagnosis panel.

Statistical analysis
--------------------

The data synthesis was performed using the statistical methods described in the protocol [@B29]. The following summary accuracy measures with corresponding 95% confidence intervals were obtained: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR). We explored the variation in the accuracy indices graphically using Forest plots and the area under the curve (AUC), a comprehensive representation of test accuracy that combines sensitivity with specificity. The heterogeneity among studies was measured using the I^2^ test. The Mantel-Haenszel fixed-effects model was applied in cases of low heterogeneity (I^2^\< 50), and the random-effects model was applied for datasets showing obvious heterogeneity (I^2^\> 50) [@B30]. The latent publication bias was assessed by a funnel plot and Deeks\' linear regression test [@B31]. All statistical analyses were conducted by Meta-Disc 1.4 (XI Cochrane Colloquium, Barcelona, Spain) and Stata Version 12.0 software (Stata Corporation, College Station, TX, USA).

Results
=======

Literature screening and study characteristics
----------------------------------------------

The process of literature screening and study selection is presented in Figure [1](#F1){ref-type="fig"}. After a preliminary online search, a total of 458 potentially relevant articles were retrieved from the EMBASE, MEDLINE and Web of Science library databases. Of these, 402 articles were excluded after a manual screening of titles, abstracts and key words because they were duplicates or irrelevant to the current analysis. After a careful review of the full texts of the remaining 56 studies, another 48 were removed in accordance with the inclusion and exclusion criteria. Finally, 8 eligible studies with 1235 participants in total were enrolled in this meta-analysis [@B7], [@B8], [@B24], [@B32]-[@B36].

The basic information and main characteristics of the eligible studies are summarized in Table [1](#T1){ref-type="table"}. The participants were enrolled in these studies were from Finland, the United States, China, Turkey, Japan or Poland. The studies dealt with a wide range of gastrointestinal diseases including pancreatic cancer, pancreatic benign tumors, pancreatitis, and other gastrointestinal diseases. Pancreatic cancer was histologically or cytologically confirmed by the pathological examination of resected specimens or by fine-needle aspiration. Patients were staged according to the TNM staging criteria for pancreatic cancer in the 7th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual [@B37]. Serum samples were collected prior to operation or chemotherapy and used for detecting the levels of tumor markers including CA125, CA19-9 and CEA by electrochemiluminescence immunoassays. The level of CA125 alone was detected in all eligible articles, and its diagnostic accuracy was evaluated, while a total of 12 groups with a CA125-based tumor panel were also studied in this meta-analysis. Four studies used the critical value of CA125 (35 U/mL) as the cut-off value, while 19.7 U/mL, 32 U/mL, 33 U/mL, and 65 U/mL were used in the other studies.

QUADAS-2 assessment
-------------------

The authors\' judgment on risk of bias was determined using the revised assessment tool QUADAS-2. The overall methodological quality of the eligible studies is shown in Figure [2](#F2){ref-type="fig"}. In the area of patient selection, four studies were judged as having a low risk of bias, two were high risk due to the case-control design [@B34], [@B36], and the remaining two were unclear [@B8], [@B35]. Three studies were deemed to have a high risk of bias in the conduct of the index test, as the index test was performed after the reference standard in these studies [@B8], [@B33], [@B35]. All studies had a low risk of bias attributed to the reference standard, as this was deemed an objective histological assessment. Five of the 8 studies had a low risk of bias in patient timing and flow. Two studies were described as having a high risk of bias in this area, as not all of the patients who were recruited for these studies could be included in the analysis [@B7], [@B35]. Regarding applicability concerns, four studies were low risk for patient selection, and four studies were unclear due to the case-control design and other reasons [@B8], [@B34]-[@B36]. All studies were considered to have low risk in the applicability of the index test and reference standard.

Diagnostic accuracy assessment and clinical value
-------------------------------------------------

The variations in sensitivity, specificity, PLR and NLR between individual studies of the detection of pancreatic cancer by serum biomarker measurements were illustrated by forest plots. Eight studies including 1235 participants (602 with pancreatic cancer, 633 controls) were included in this meta-analysis. The pooling accuracy analysis of CA125 alone indicated that the pooled sensitivity was 0.59 (95% CI: 0.54-0.62), the specificity was 0.78 (95% CI: 0.75-0.82), the PLR was 2.57 (95% CI: 2.03-3.25), and the NLR was 0.52 (95% CI: 0.40-0.66) (Supplementary Figure [S1](#SM0){ref-type="supplementary-material"}). Similarly, a total of 12 groups tested with a CA125-based panel in all eligible studies were also examined in this meta-analysis. The serum CA125-based panel had a pooled sensitivity of 0.47 (95% CI 0.47-0.51), a specificity of 0.88 (95% CI 0.86-0.90), a PLR of 6.83 (95% CI: 4.18-11.13), and an NLR of 0.50 (95% CI: 0.40-0.62) (Supplementary Figure [S2](#SM0){ref-type="supplementary-material"}). In addition, the pooling accuracy of CA19-9 alone was also determined in this meta-analysis (Supplementary Figure [S3](#SM0){ref-type="supplementary-material"}). The pooled results are listed in Table [2](#T2){ref-type="table"}. The heterogeneity of these studies was tested by the I-square values of sensitivity, specificity, PLR, NLR and DOR. From the results, we can see that there was significant heterogeneity between these studies, so the pooled indicators were calculated using the random effect model.

The summary receiver operating characteristic (SROC) curve for the tumor diagnostic indicators was drawn based on true-positive rates (sensitivity) for the vertical axis and false-positive rates (1-specifity) for the horizontal axis. An AUC close to 1 reflected a well-performing diagnostic indicator, and poor performance is indicated by an AUC close to 0.5 [@B37]. As an overall diagnostic indicator, the Q-value is the intersection of the SROC curve with a diagonal line of the ROC diagram from the left upper corner to the right lower corner, reflecting the highest diagnostic value of both sensitivity and specificity. In this meta-analysis, the AUC and Q-value of the CA125-based diagnostic panel were 0.89 and 0.82, respectively (Figure [3](#F3){ref-type="fig"}), which is higher than that of CA19-9 alone or CA125 alone (Supplementary Figure [S4](#SM0){ref-type="supplementary-material"}).

Publication bias
----------------

The publication bias of the included studies was assessed by funnel plots and Deeks\' tests in this meta-analysis. Formal testing for publication bias may be conducted by a regression of the diagnostic log odds ratio (lnDOR) against the square root of the effective sample size (1/ESS1/2), weighting by ESS, with P \< 0.05 for the slope coefficient indicating significant asymmetry [@B31]. Publication bias was not found in this meta-analysis according to both the funnel plot, which is almost symmetric, and Deeks\' test (P = 0.164). The funnel plot is shown in Figure [4](#F4){ref-type="fig"}.

Discussion
==========

The correct and effective diagnosis of pancreatic cancer remains an area of intensive research. Diagnostic limitations still exist in terms of sensitivity, specificity, and cost-effectiveness, although various diagnostic imaging techniques are more or less useful than others. As a relatively simple and reliable noninvasive diagnostic technique, various serum markers of potential value in the diagnosis of pancreatic cancer have been evaluated, especially CA19-9, CA125 and CEA [@B25], [@B32]. Though the CA 19-9 test has certain limitations regarding its sensitivity, as a leading tumor marker, it is still used in the diagnosis of pancreatic carcinoma owing to its high specificity. In pancreatic cancer, many studies have investigated the diagnostic value of CA125, though some have used small sample sizes and retrospective reports. In addition, no meta-analyses have formerly been performed on the diagnostic significance of CA125 in pancreatic cancer. To clarify the clinical value of CA125 and explore its role in the diagnosis of pancreatic cancer, we carried out a meta-analysis.

In the current meta-analysis, which pooled global high-quality studies concerning biomarkers and pancreatic cancer diagnosis, it was demonstrated that the specificity of CA125-based diagnostic panels including CA125/CEA, CA125/CA19-9 and CA125/CEA/CA19-9 was superior to CA125 or CA19-9 alone. Nevertheless, these panels also have some limitations in terms of their sensitivity. As an evaluation index of the overall performance of diagnostic tests, the DOR has significant advantages, in that it is not affected by the morbidity and takes into account the sensitivity and specificity. The pooled DOR of CA125-based diagnostic panels was 19.75, indicating a higher diagnostic accuracy. Similarly, the AUC is also a very important indicator of diagnostic accuracy, similar to the DOR. In the current meta-analysis, the AUC of the CA19-9 test was 0.85. This result was similar to those described by others, where the AUC of the CA19-9 test ranged between 72% and 87% [@B38]-[@B40]. The AUC of the CA125-based diagnostic panel was 0.89, which demonstrates a better diagnostic capability compared with CA125 or CA19-9 alone. Hence, these indicators reflect the promising clinical value of the CA125-based diagnostic panel as a diagnostic biomarker.

CA125, which is encoded by the MUC16 gene, is primarily known as a useful serological marker for the clinical management of ovarian cancer [@B41]. However, an increasing number of studies have proposed a role for serum CA125 as a marker for pancreatic carcinoma diagnosis. More importantly, since serum levels of CA125 are not correlated with serum bilirubin levels, its positivity is not significantly different between the jaundiced and non-jaundiced subgroups of patients with both pancreatic carcinoma and benign pancreatic diseases [@B8], [@B42], which is superior to the serum CA19-9 test. Hence, CA125 can be useful in the diagnosis of pancreatic cancer, especially in jaundiced patients.

Furthermore, it was demonstrated that CA125 could also play an important role in predicting survival in these patients. In this field, our team has previously performed a series of relevant studies [@B24]-[@B26], [@B42]. A CEA+/CA125+/CA19-9 \>1000 U/mL serum signature was identified as a preoperative indicator for surgical outcome in pancreatic cancer, which implied that patients with this index hardly benefited from pancreatectomy, even if the resection was successful with an R0-definition [@B24], [@B26]. Abnormally high levels of CA125 were observed in some patients who underwent pancreatectomy and experienced early postoperative metastasis at distant organs, which may indicate that CA125 is a valuable clinical biomarker of occult disease in pancreatic cancer [@B24], [@B25]. In addition, an elevated preoperative CA125 level was an independent prognostic factor for pancreatic cancer patients with non-elevated bilirubin or hyperbilirubinemia [@B42]. These theories support the clinical value of the serum CA125 level in predicting pancreatic cancer.

Several limitations should be considered in the current meta-analysis. First, the sample size was still small. Though we pooled all participants in the eligible studies, some were excluded due to the involvement of other gastrointestinal cancers, and only 1235 participants were studied in the analysis of overall diagnosis. Second, the heterogeneity of the population was increased due to differences in patient characteristics (age, race, country, etc.) and cut-off criteria. Third, only studies published in English were included in our meta-analysis, which may also result in bias. Finally, in order to further validate the CA125-based diagnostic panel in the diagnosis of pancreatic cancer, we need more multi-center, prospective clinical studies. Thus, our results might be flawed to some extent.

Conclusions
===========

In summary, the present meta-analysis, representing a quantified synthesis of the published studies, has shown that a CA125-based diagnostic panel is better at diagnosing pancreatic cancer than testing CA125 or CA19-9 alone. As it is the most economic, convenient, safe and rapid method, the CA125-based diagnostic panel should be widely used to complement other diagnostic techniques. However, further studies are required to confirm our conclusion.
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###### 

Characteristics of the Included Studies

  ---------------------------------------------------------------------------------------------------------------------------------
  Author           Year   Origin of patients   NO. of sample   Sample\   TP\   FP\   FN\   TN\   CA125\    diagnosis\
                                                               origin    (%)   (%)   (%)   (%)   Cut-off   biomarker
  ---------------- ------ -------------------- --------------- --------- ----- ----- ----- ----- --------- ------------------------
  Haglund et al    1986   Finland              201             Serum     74    24    21    82    \-        CA19-9

  Haglund et al    1986   Finland              201             Serum     43    26    52    80    35        CA125

  Haglund et al    1986   Finland              201             Serum     39    7     56    99    35        CA125,CA19-9

  Haglund et al    1986   Finland              201             Serum     34    7     53    99    35        CA125, CEA

  Haglund et al    1986   Finland              201             Serum     31    1     56    105   35        CA125,CEA,CA19-9

  Sakamoto et al   1987   Japan                61              Serum     26    2     4     29    \-        CA19-9

  Sakamoto et al   1987   Japan                61              Serum     19    1     11    30    32        CA125

  Sakamoto et al   1987   Japan                61              Serum     26    8     4     23    32        CA125,CEA

  Sakamoto et al   1987   Japan                61              Serum     29    2     1     29    32        CA125,CA19-9

  Benini et al     1988   America              68              Serum     14    6     11    37    \-        CA19-9

  Benini et al     1988   America              68              Serum     14    6     11    37    65        CA125

  Benini et al     1988   America              193             Serum     19    42    6     126   65        CA125,CEA

  Benini et al     1988   America              193             Serum     24    40    6     128   65        CA125,CA19-9

  C wik et al      2006   Poland               110             Serum     59    4     15    32    \-        CA19-9

  C wik et al      2006   Poland               110             Serum     45    6     29    30    35        CA125

  C wik et al      2006   Poland               110             Serum     39    2     35    34    35        CA125,CA19-9

  Duraker et al    2007   Turkey               181             Serum     100   14    23    44    \-        CA19-9

  Duraker et al    2007   Turkey               181             Serum     70    13    53    45    35        CA125

  Duraker et al    2007   Turkey               181             Serum     38    1     85    57    35        CA125,CEA

  Duraker et al    2007   Turkey               181             Serum     57    4     66    54    35        CA125,CA19-9

  Duraker et al    2007   Turkey               181             Serum     33    1     90    57    35        CA125,CEA,CA19-9

  Luo et al        2013   China                212             Serum     107   22    29    54    19.7      CA125

  Wang et al       2013   China                145             Serum     55    10    20    60    \-        CA19-9

  Wang et al       2013   China                145             Serum     23    8     52    62    33        CA125

  Gu et al         2015   China                132             Serum     43    33    9     47    \-        CA19-9

  Gu et al         2015   China                132             Serum     36    26    16    54    35        CA125

  Gu et al         2015   China                132             Serum     47    5     5     75    35        CA125,CEA,CA19-9,CA242
  ---------------------------------------------------------------------------------------------------------------------------------

TP, true positive rate; FP, false positive rate; TN, true negative rate; FN, false negative rate

###### 

Pooled diagnostic accuracy

  -------------------------------------------------------------------------------------------------------------------------------------------------------
                           Diagnostic\        Sensitivity\       Specificity\       PLR\               NLR\                  DOR\                 AUC\
                           biomarker          (95%CI)            (95%CI)            (95%CI)            (95%CI)               (95%CI)              (SEM)
  ------------------------ ------------------ ------------------ ------------------ ------------------ --------------------- -------------------- -------
  PC vs non-PC             CA19-9             0.78 (0.74-0.82)   0.78 (0.74-0.82)   3.95 (2.60-6.00)   0.29 (0.23-0.36)      14.09 (8.84-22.45)   0.85

  CA125                    0.59 (0.54-0.62)   0.78 (0.75-0.82)   2.57 (2.03-3.25)   0.52 (0.40-0.66)   5.45 (3.50-8.49)      0.76                 

  CA125-based panel        0.47 (0.47-0.51)   0.88 (0.86-0.90)   6.83(4.18-11.13)   0.50 (0.40-0.62)   19.75 (11.35-34.36)   0.89                 

  Heterogeneity, I^2^(P)   CA19-9             39.9% (0.125)      78.6% (0.000)      74.9% (0.000)      40.5% (0.121)         41.4% (0.115)        \-

  CA125                    88.0% (0.000)      70.6% (0.001)      32.3% (0.170)      81.9% (0.000)      53.2% (0.036)         \-                   

  CA125-based panel        93.4% (0.000)      88.4% (0.000)      78.5% (0.000)      89.6% (0.000)      54.7% (0.011)         \-                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------

PC, pancreatic cancer; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, the area under the curve; CI, confidence interval.
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